A Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder
Overview
- Phase
- Phase 2
- Intervention
- Nabiximols
- Conditions
- Post-Traumatic Stress Disorder
- Sponsor
- Jazz Pharmaceuticals
- Primary Endpoint
- Change from Baseline in Clinician Administered Post-Traumatic Stress Disorder (PTSD) Scale (Clinician Administered PTSD Scale [CAPS-5]) Score over 8 Weeks
- Status
- Withdrawn
- Last Updated
- 3 years ago
Overview
Brief Summary
This study will be conducted to evaluate the efficacy of nabiximols for the treatment of symptoms of post-traumatic stress disorder (PTSD) in participants receiving selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) pharmacotherapy.
Detailed Description
This multicenter, randomized, double-blind, placebo-controlled, parallel-group trial includes a screening period of up to 28 days, an 8-week treatment period (comprising a 2-week titration phase and a 6-week maintenance phase), and a 2-week follow-up period. At screening (Visit 1), all participants will receive instructions on how to complete a writing exercise (Exposure Writing Exercise) related to their traumatic experience. Prior to the baseline visit (Visit 2), participants must complete an approximate 30-minute writing exercise outside of the trial site and should have re-read the write up at least once to be eligible for enrollment. Throughout the screening and treatment periods, the dose of SSRI/SNRI used as background therapy, if any, should remain unchanged. On Day 1, eligible participants will be randomly assigned to either nabiximols or placebo in a 1:1 ratio. Participants will be advised to titrate the investigational medicinal product (IMP), beginning with 1 spray/day, to an optimized dose that relieves their most bothersome symptom of PTSD or to a maximum of 12 sprays/day over the first 14 days of treatment. Participants should continue at the same dose level achieved at the end of the titration phase ±1 spray divided into a morning dose and an evening dose for the remainder of the treatment period. Health-related quality of life, safety, and tolerability will be evaluated during the treatment period. Participants who complete the trial will participate for a total of approximately 14 weeks (99 days), including the 28-day Screening period.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Meets Diagnostic and Statistical Manual of Mental Disorders, Volume 5 (DSM-5) criteria for post-traumatic stress disorder (PTSD), confirmed on the basis of the Mini International Neuropsychiatric Interview (MINI)
- •If currently taking a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for the treatment of PTSD, SSRI/SNRI doses should be consistent with approved labelling and have been stable for at least 6 weeks prior to Visit 1 with no more than 1 SSRI/SNRI.
- •If not currently taking a SSRI or SNRI, should not have received treatment with either a SSRI or SNRI for at least 6 weeks prior to Visit 1 and is not planning to start additional pharmacotherapy during the study
- •Exhibits significant PTSD symptoms and associated impairment (as reflected by Clinician Administered PTSD Scale \[CAPS-5\] ≥ 27 and Clinical Global Impressions Severity \[CGI-S\] ≥ 4 at Visit 1), which should have persisted over a period of at least 3 months prior to Visit 1
- •Willing to allow the responsible authorities to be notified of participation in the trial, if mandated by local law
- •Willing to allow his or her primary care practitioner (if they have one) and consultant (if they have one) to be notified of participation in the trial, if the primary care practitioner/consultant is different to the investigator
Exclusion Criteria
- •Is at risk of suicide as evidenced by a history of suicide attempt(s) in the 2 years prior to Visit 1 or answering yes on item 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) in the month prior to Visit 1
- •Is currently involved in any legal action that relates to the diagnosis of PTSD or the traumatic events that gave rise to the disease
- •Has cognitive impairment that in the opinion of the investigator may interfere with participation in the study or ability to complete assessments or report treatment effects
- •Has any history of psychosis (including schizophrenia, schizophreniform disorder, schizoaffective disorder, or substance-induced psychosis), or bipolar disorder based on an assessment using the MINI.
- •Participants who have an index trauma before age 18 and no other traumatic experiences which could relate/identify as being part of their PTSD
- •Has taken cannabis or a cannabis derived product for medicinal or recreational purposes at any time in the past and developed significant adverse experiences related to cannabis use per history and investigator judgment
- •Has severe depressive symptoms as per the investigator's judgment or a score ≥ 20 on the Patient Health Questionnaire-9 (PHQ-9) at Visit 1
- •Has a history of any degree of DSM-5 cannabis or other substance use disorder, or moderate to severe alcohol use disorder within 6 months prior to Visit
- •Participants with Nicotine Use Disorder are allowed to enroll.
- •Has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the investigational medicinal product
Arms & Interventions
Nabiximols
Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Each spray delivers 100 microliters (μL) of nabiximols.
Intervention: Nabiximols
Placebo
Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 μL containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 8 weeks.
Intervention: Placebo
Outcomes
Primary Outcomes
Change from Baseline in Clinician Administered Post-Traumatic Stress Disorder (PTSD) Scale (Clinician Administered PTSD Scale [CAPS-5]) Score over 8 Weeks
Time Frame: Baseline; Week 8
Secondary Outcomes
- Number of Participants Exhibiting Improvements Rated as Much or Very Much Improved on the Clinical Global Impressions Improvement (CGI-I) Scale at the End of Treatment (over 8 Weeks)(from Baseline up to Week 8)
- Change from Baseline in the Self-Reported PTSD Checklist for the Diagnostic and Statistical Manual of Mental Disorders, Volume 5 (DSM-5) (PCL-5) Score over 8 Weeks(Baseline; Week 8)
- Number of Participants with the Indicated Change from Baseline in Clinical Laboratory Test Values(Baseline; Week 8)
- Change from Baseline in Diastolic Blood Pressure(Baseline; Week 8)
- Change from Baseline in Pulse Rate(Baseline; Week 8)
- Number of Participants with Clinically Significant 12-Lead Electrocardiogram (ECG) Parameter Values(from Baseline up to 8 weeks)
- Number of Participants with any Treatment-Emergent Adverse Event(up to Week 8)
- Change from Baseline in Systolic Blood Pressure(Baseline; Week 8)
- Change from Baseline in the Columbia-Suicide Severity Rating Scale (C-SSRS) Score(Baseline; Week 8)